Abstract

Simple SummaryMolecular components of extracellular vesicles present in serum are potential biomarkers of lung cancer, however, none of them have been validated in the context of an actual early detection of lung cancer. Here, we compared the lipid profiles of vesicles obtained from participants in a lung cancer screening study, including patients with screening-detected cancer and individuals with benign pulmonary nodules or without pathological changes. A few lipids whose levels were different between compared groups were detected, including ceramide Cer(42:1) upregulated in vesicles from cancer patients. Furthermore, a high heterogeneity of lipid profiles of extracellular vesicles was observed, which impaired the performance of classification models based on specific compounds.Molecular components of exosomes and other classes of small extracellular vesicles (sEV) present in human biofluids are potential biomarkers with possible applicability in the early detection of lung cancer. Here, we compared the lipid profiles of serum-derived sEV from three groups of lung cancer screening participants: individuals without pulmonary alterations, individuals with benign lung nodules, and patients with screening-detected lung cancer (81 individuals in each group). Extracellular vesicles and particles were purified from serum by size-exclusion chromatography, and a fraction enriched in sEV and depleted of low-density lipoproteins (LDLs) was selected (similar sized vesicles was observed in all groups: 70–100 nm). The targeted mass-spectrometry-based approach enabled the detection of 352 lipids, including 201 compounds used in quantitative analyses. A few compounds, exemplified by Cer(42:1), i.e., a ceramide whose increased plasma/serum level was reported in different pathological conditions, were upregulated in vesicles from cancer patients. On the other hand, the contribution of phosphatidylcholines with poly-unsaturated acyl chains was reduced in vesicles from lung cancer patients. Cancer-related features detected in serum-derived sEV were different than those of the corresponding whole serum. A high heterogeneity of lipid profiles of sEV was observed, which markedly impaired the performance of classification models based on specific compounds (the three-state classifiers showed an average AUC = 0.65 and 0.58 in the training and test subsets, respectively).

Highlights

  • Lung cancer is the leading cause of cancer mortality, responsible for about one-fifth of cancer-related deaths worldwide

  • A few lipids detected in serum-derived small extracellular vesicles (sEV) showed different levels between samples of healthy participants in the lung cancer screening study and pre-diagnostic samples of patients with screening-detected lung cancer

  • This was exemplified by ceramide Cer(42:1), a compound whose increased plasma/serum level was reported in different pathological conditions, being upregulated in vesicles from cancer patients

Read more

Summary

Introduction

Lung cancer is the leading cause of cancer mortality, responsible for about one-fifth of cancer-related deaths worldwide. The majority of lung cancer cases are diagnosed at advanced stages and have a poor prognosis (average 5-year survival of about 10–15%). In the case of diseases detected at early stages, the prognosis is much better (the average 5-year survival in the range of 65–85%). Low dose computed tomography (LDCT) screening in high-risk groups is the most efficacious strategy for lung screening, with a perspective for worldwide cancer mortality reduction [3,4]. Complementation of LDCT-based imaging with other clinical or molecular tests allowing for effective and reliable pre-selection of individuals for LDCT examination, or for better discrimination between benign and malignant nodules detected by LDCT, seems to be a critical issue for the practical application of the lung cancer screening strategy [6]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call